Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Mar 30, 2022 9:50pm
128 Views
Post# 34561343

Another positive reference to IgA......SQI's EXACT

Another positive reference to IgA......SQI's EXACTAntibody Test is bang on with its 6 targets including IgA for both S and N protein.  
 

Nasal nanoparticle (NP) vaccines for 
#COVID19.

The NPs can be polysaccharides, lipids or proteins, polymers or biomimetics.

Nasal vaccines are part of the mucosal vaccines, including oral and spray vaccines.

These go to the mucosa-associated lymphatic tissues (MALT) of the nose, intestine, lungs, and other body openings.

Aerosolized vaccines elicit mucosal and systemic immunity via bronchus-associated lymphatic tissue (BALT).

Nasal vaccines produce high levels of neutralizing antibodies as well as immunoglobulin A (IgA) and T cell responses in the mucosa that clear the virus from the upper and lower respiratory tract.

Antigen-specific IgA prevents viral adherence to and infection of the epithelium, thus safeguarding the mucosal barrier (IgA antibodies are not typically produced by intramuscular vaccines).

Antigen-presenting dendritic cells present the viral antigens to the nasopharynx-associated lymphatic tissue (NALT) throughout the oropharynx and nasopharynx, stimulating both mucosal and systemic immunity.

Anti-spike and anti-envelope #SARSCoV2 antibodies can neutralize the corresponding antigens and the virus within the dendritic cells.

After NPs enter the nasal cavity, they linger briefly in the nasal mucosa before entering the epithelial cells of the airway.

The time spent in the mucus is dependent on the size of the NPs, the charge, and chemical composition.

Both passive entry as well as endocytosis have been noted to occur in the nasal mucosa.

They may be directly captured by dendritic cells or by M cells.

Once this occurs, mucosal immunity is elicited, preventing future viral entry more effectively than the humoral immunity produced by injectable vaccines.


                                                                                           Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19 mdpi.com • 2 min read                                                                           
<< Previous
Bullboard Posts
Next >>